Journal of Diagnostics Concepts & Practice >

2025 , Vol. 24 >Issue 06: 654 - 659

DOI: https://doi.org/10.16150/j.1671-2870.2025.06.012

Review articles

Research progress on resistance mechanisms of group B Streptococcus to macrolides and lincosamide antibiotics

  • SHEN Pinghua ,
  • CHEN Huifeng
Expand
  • Department of Laboratory， Shanghai First Maternity and infant Hospital， School of Medicine， Tongji University， Shanghai 200040， China

Received date: 2024-07-19

  Revised date: 2025-10-27

  Online published: 2025-12-25

Fold

Abstract

Group B Streptococcus (GBS) is a major pathogen causing neonatal infection worldwide, and the colonization of GBS in the digestive and urogenital tracts of pregnant women is the main risk factor for neonatal infection. The global overall maternal GBS colonization rate is 18%, with 12.5% in South Asia, 11% in East Asia, and 11.3% in China. Without intervention, 50% of maternal GBS will be vertically transmitted to the fetus or neonate, which is a major cause of early-onset GBS disease in neonates and can lead to neonatal sepsis and neonatal meningitis. A study in 2015 indicated that neonatal invasive diseases caused by GBS infection globally resulted in 90 000 infant deaths, 3.5 million preterm births, and 57 000 stillbirths. Currently, some countries have adopted intrapartum antibiotic prophylaxis (IAP) to prevent the transmission of GBS from mother to neonate during delivery. In IAP, macrolide antibiotics such as erythromycin and lincosamide antibiotics such as clindamycin serve as second-line antibiotics and play an important role in anti-GBS infection. However, the resistance rates to antibiotics such as erythromycin and clindamycin remain high, with global resistance rates of approximately 25% and 27%, respectively. The resistance rates in China are even higher, at about 75% and 60%, respectively. The resistance mechanisms of GBS to the above two classes of antibiotics mainly include target modification, efflux pumps, ribosome protection by ABC-F proteins, and drug inactivation. These resistance mechanisms are increasingly diverse and mostly associated with mobile elements, accelerating the dissemination of resistance genes. There is an urgent need for clinicians and researchers to work together, strictly implement scientific management of antimicrobial drugs, and actively develop new antimicrobial agents, thereby preventing the spread of resistance genes.

Key words： Group B Streptococcus; Erythromycin; Clindamycin; Resistance mechanisms

Cite this article

SHEN Pinghua , CHEN Huifeng . Research progress on resistance mechanisms of group B Streptococcus to macrolides and lincosamide antibiotics[J]. Journal of Diagnostics Concepts & Practice, 2025 , 24(06) : 654 -659 . DOI: 10.16150/j.1671-2870.2025.06.012

References

[1] RUSSELL N J, SEALE A C, O' DRISCOLL M, et al. Maternal colonization with group B Streptococcus and serotype distribution worldwide: Systematic review and meta-analyses[J]. Clin Infect Dis, 2017, 65(suppl_2): S100-S111.
[2] RUSSELL N J, SEALE A C, O SULLIVAN C, et al. Risk of early-onset neonatal group B Streptococcal disease with maternal colonization worldwide: Systematic review and meta-analyses[J]. Clin Infect Dis, 2017, 65(suppl_2): S152-S159.
[3] SEALE A C, BIANCHI-JASSIR F, RUSSELL N J, et al. Estimates of the burden of group B Streptococcal disease worldwide for pregnant women, stillbirths, and children[J]. Clin Infect Dis, 2017, 65(suppl_2):S200-S219.
[4] DING Y, WANG Y, HSIA Y, et al. Systematic review and meta-analyses of incidence for group B Streptococcus di-sease in infants and antimicrobial resistance, China[J]. Emerg Infect Dis, 2020, 26(11): 2651-2659.
[5] ZHU Y, LIN X Z. Updates in prevention policies of early-onset group B Streptococcal infection in newborns[J]. Pediatr Neonatol, 2021, 62(5):465-475.
[6] LECLERCQ R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications[J]. Clin Infect Dis, 2002, 34(4):482-492.
[7] DHAWAN V K, THADEPALLI H. Clindamycin: a review of fifteen years of experience[J]. Rev Infect Dis, 1982, 4(6):1133-1153.
[8] DUNKLE J A, XIONG L, MANKIN A S, et al. Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action[J]. Proc Natl Acad Sci U S A, 2010, 107(40):17152-17157.
[9] HUANG J, LI S, LI L, et al. Alarming regional differences in prevalence and antimicrobial susceptibility of group B Streptococci in pregnant women: A systematic review and meta-analysis[J]. J Glob Antimicrob Resist, 2016, 7: 169-177.
[10] NANDURI S A, PETIT S, SMELSER C, et al. Epidemio-logy of invasive early-onset and late-onset group B Streptococcal disease in the United States, 2006 to 2015: Multistate Laboratory and population-based surveillance[J]. JAMA Pediatr, 2019, 173(3):224-233.
[11] FRANCOIS W L, MCGEE L, SCHRAG S J, et al. Epidemiology of invasive group B Streptococcal infections among nonpregnant adults in the United States, 2008-2016[J]. JAMA Intern Med, 2019, 179(4):479-488.
[12] MATANI C, TREZZI M, MATTEINI A, et al. Streptococcus agalactiae: prevalence of antimicrobial resistance in vaginal and rectal swabs in Italian pregnant women[J]. Infez Med, 2016, 24(3):217-221.
[13] HAYES K, COTTER L, BARRY L, et al. Emergence of the L phenotype in group B Streptococci in the South of Ireland[J]. Epidemiology and Infection, 2017, 145(16):3535-3542.
[14] BJORNSDOTTIR E S, MARTINS E R, ERLENDSDOTTIR H, et al. Changing epidemiology of group B Streptococcal infections among adults in Iceland: 1975-2014[J]. Clin Microbiol Infect, 2016, 22(4):379.
[15] VINNEMEIER C D, BRUST P, OWUSU-DABO E, et al. Group B Streptococci serotype distribution in pregnant women in Ghana: assessment of potential coverage through future vaccines[J]. Trop Med Int Health, 2015, 20(11):1516-1524.
[16] BOTELHOA, OLIVEIRAJ G, DAMASCOA P, et al. Streptococcus agalactiae carriage among pregnant women living in Rio de Janeiro, Brazil, over a period of eight years[J]. PLoS One, 2018, 13(5): e196925.
[17] WEISBLUM B. Erythromycin resistance by ribosome modification[J]. Antimicrob Agents Chemother, 1995, 39(3):577-585.
[18] ROBERTS M C, SUTCLIFFE J, COURVALIN P, et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants[J]. Antimicrob Agents Chemother, 1999, 43(12):2823-2830.
[19] PALMIERI C, MAGI G, CRETI R, et al. Interspecies mobilization of an ermT-carrying plasmid of Streptococcus dysgalactiae subsp. equisimilis by a coresident ICE of the ICESa2603 family[J]. J Antimicrob Chemother, 2013, 68(1):23-26.
[20] COMPAIN F, HAYS C, TOUAK G, et al. Molecular characterization of Streptococcus agalactiae isolates harboring Smallerm (T)-carrying plasmids[J]. Antimicrob Agents Chemother, 2014, 58(11):6928-6930.
[21] DEPARDIEU F, PODGLAJEN I, LECLERCQ R, et al. Modes and modulations of antibiotic resistance gene expression[J]. Clin Microbiol Rev, 2007, 20(1):79-114.
[22] LUNA V A, COATES P, EADY E A, et al. A variety of gram-positive bacteria carry mobile mef genes[J]. J Antimicrob Chemother, 1999, 44(1):19-25.
[23] SHARKEY L K, EDWARDS T A, O'NEILL A J. ABC-F proteins mediate antibiotic resistance through ribosomal protection[J]. mBio, 2016, 7(2): e1975.
[24] SHARKEY L, O'NEILL A J. Antibiotic resistance ABC-F proteins: bringing target protection into the limelight[J]. ACS Infect Dis, 2018, 4(3):239-246.
[25] MURINA V, KASARI M, HAURYLIUK V, et al. Antibio-tic resistance ABCF proteins reset the peptidyl transfera-se centre of the ribosome to counter translational arrest[J]. Nucleic Acids Res, 2018, 46(7):3753-3763.
[26] MALBRUNY B, WERNO A M, ANDERSON T P, et al. A new phenotype of resistance to lincosamide and streptogramin A-type antibiotics in Streptococcus agalactiae in New Zealand[J]. J Antimicrob Chemother, 2004, 54(6):1040-1044.
[27] MALBRUNY B, WERNO A M, MURDOCH D R, et al. Cross-resistance to lincosamides, streptogramins A, and pleuromutilins due to the lsa(C) gene in Streptococcus agalactiae UCN70[J]. Antimicrob Agents Chemother, 2011, 55(4):1470-1474.
[28] HAWKINS P A, LAW C S, METCALF B J, et al. Cross-resistance to lincosamides, streptogramins A and pleuromutilins in Streptococcus agalactiae isolates from the USA[J]. J Antimicrob Chemother, 2017, 72(7):1886-1892.
[29] DOUARRE P E, SAUVAGE E, POYART C, et al. Host specificity in the diversity and transfer of lsa resistance genes in group B Streptococcus[J]. J Antimicrob Chemother, 2015, 70(12): 3205-3213.
[30] GOLKAR T, ZIELINSKI M, BERGHUIS A M. Look and Outlook on Enzyme-Mediated Macrolide Resistance[J]. Front Microbiol, 2018, 9:1942.
[31] DE AZAVEDO J C, MCGAVIN M, DUNCAN C, et al. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B Streptococcus isolates from Ontario, Canada[J]. Antimicrob Agents Chemother, 2001, 45(12):3504-3508.
[32] GAO K, GUAN X, ZENG L, et al. An increasing trend of neonatal invasive multidrug-resistant group B Streptococcus infections in southern China, 2011-2017[J]. Infect Drug Resist, 2018, 11:2561-2569.
[33] BOLUKAOTO J Y, MONYAMA C M, CHUKWU M O, et al. Antibiotic resistance of Streptococcus agalactiae isolated from pregnant women in Garankuwa, South Africa[J]. BMC Res Notes, 2015, 8:364.
[34] MOROI H, KIMURA K, IDO A, et al. Erythromycin-susceptible but clindamycin-resistant phenotype of clinical ermB-PCR-positive group B Streptococci isolates with IS1216E-inserted ermB[J]. Jpn J Infect Dis, 2019, 72(6):420-422.
[35] ZHI Y, JI H J, JUNG J H, et al. Molecular characteristics of IS 1216 carrying multidrug resistance gene cluster in serotype Ⅲ/sequence type 19 group B Streptococcus[J]. mSphere, 2021, 6(4): e54321.
[36] ACHARD A, LECLERCQ R. Characterization of a small mobilizable transposon, MTnSag1, in Streptococcus agalactiae[J]. J Bacteriol, 2007, 189(11):4328-4331.
[37] 王胜泉, 华颖, 孙明霞, 等. 多西环素与阿奇霉素治疗8岁以上儿童支原体肺炎的疗效和安全性比较[J]. 中国临床研究, 2025, 38(1):110-112,117.
  WANG S Q, HUA Y, SUN M X, et al. Comparison of efficacy and safety of doxycycline versus azithromycin formycoplasma pneumonia in children over 8 years old[J]. Chin J Clin Res, 38 (1):110-112,117.
Options
Outlines

/

〈 〉